Virtu KCG Holdings LLC acquired a new position in Immune Design Corp. (NASDAQ:IMDZ) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 15,706 shares of the biotechnology company’s stock, valued at approximately $153,000. Virtu KCG Holdings LLC owned 0.06% of Immune Design Corp. as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds have also made changes to their positions in the business. Victory Capital Management Inc. grew its holdings in Immune Design Corp. by 2.1% in the second quarter. Victory Capital Management Inc. now owns 1,977,564 shares of the biotechnology company’s stock worth $19,281,000 after purchasing an additional 40,010 shares during the period. Franklin Resources Inc. grew its holdings in Immune Design Corp. by 2.7% in the second quarter. Franklin Resources Inc. now owns 760,253 shares of the biotechnology company’s stock worth $7,412,000 after purchasing an additional 20,000 shares during the period. JPMorgan Chase & Co. grew its holdings in Immune Design Corp. by 118.7% in the second quarter. JPMorgan Chase & Co. now owns 530,702 shares of the biotechnology company’s stock worth $5,175,000 after purchasing an additional 288,009 shares during the period. Vanguard Group Inc. grew its holdings in Immune Design Corp. by 37.9% in the second quarter. Vanguard Group Inc. now owns 524,999 shares of the biotechnology company’s stock worth $5,118,000 after purchasing an additional 144,408 shares during the period. Finally, FMR LLC grew its holdings in Immune Design Corp. by 0.4% in the first quarter. FMR LLC now owns 445,152 shares of the biotechnology company’s stock worth $3,027,000 after purchasing an additional 1,699 shares during the period. Institutional investors and hedge funds own 51.44% of the company’s stock.
Shares of Immune Design Corp. (NASDAQ IMDZ) opened at 4.60 on Tuesday. Immune Design Corp. has a 12-month low of $3.78 and a 12-month high of $13.05. The stock’s market cap is $117.85 million. The stock’s 50 day moving average is $8.98 and its 200-day moving average is $8.52.
Immune Design Corp. (NASDAQ:IMDZ) last issued its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.11. Immune Design Corp. had a negative net margin of 324.33% and a negative return on equity of 59.14%. The firm had revenue of $0.73 million for the quarter, compared to the consensus estimate of $1.50 million. Equities analysts expect that Immune Design Corp. will post ($2.29) EPS for the current year.
In other news, Director Peter Svennilson acquired 2,681,000 shares of the business’s stock in a transaction dated Friday, October 27th. The shares were purchased at an average price of $4.10 per share, with a total value of $10,992,100.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Franklin M. Berger acquired 25,000 shares of the business’s stock in a transaction dated Wednesday, October 25th. The stock was purchased at an average cost of $4.26 per share, for a total transaction of $106,500.00. Following the transaction, the director now owns 50,000 shares in the company, valued at $213,000. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 2,786,000 shares of company stock worth $11,535,500. Insiders own 20.70% of the company’s stock.
A number of equities research analysts have weighed in on IMDZ shares. Zacks Investment Research upgraded shares of Immune Design Corp. from a “hold” rating to a “buy” rating and set a $11.00 price objective on the stock in a report on Tuesday, July 18th. BidaskClub cut shares of Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 5th. ValuEngine upgraded shares of Immune Design Corp. from a “sell” rating to a “hold” rating in a report on Friday, August 11th. Royal Bank Of Canada initiated coverage on shares of Immune Design Corp. in a report on Thursday, September 14th. They set an “outperform” rating and a $20.00 price target on the stock. Finally, Wells Fargo & Company cut shares of Immune Design Corp. from an “outperform” rating to a “market perform” rating and cut their price target for the company from $29.00 to $10.00 in a report on Tuesday, October 17th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $14.75.
About Immune Design Corp.
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
What are top analysts saying about Immune Design Corp.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Immune Design Corp. and related companies.